The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.Jedinjenje formule ili njegova farmaceutski prihvatljiva so, za upotrebu u tretmanu kancera u kombinaciji sa anti-PD-1 antitelom gde su:W, X1, i X2 nezavisno izabrani od (CRaRbt„ (CRaRb)uO(CRaRb)v, (CRaRb)uC(O)(CRaRb)v, (CRaRb)uC(O)NRc(CRaRb)v, (CRaRb)uC(O)O(CRaRb)v, (CRaRb)uC(S)(CRaRb)u, (CRaRb)uC(S)NRc(CRaRb)v, (CRaRb)uS(O)(CRaRb)v, (CRaRb)uS(O)NRc(CRaRb)v, (CRaRb)uS(O)2(CRaRb)v, (CRaRb)uS(O)2NRc(CRaRb)v, (CRaRb)uNRc(CRaRb)v i (CRaRb)uC(=NRd)N Rc(CRaRb)v；R2 je H, C1-6alkil ili C3-7cikloalkil；R3a i R5a su nezavisno izabrani od C1-8 alkila, C2-8 alkenila, C2-8 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila, svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, Cy1, CN, N O2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NR91Rh1, NRg1C(O)NRg1Rf1, NRg1Rh1, NRg1C(O)Rf1, NRg1C(O)ORe1, C(=NRf)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rfl, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1；R3b je aril ili heteroaril svaki opciono supstituisan sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-4 haloalkila, C1-4 hidroksialkila, Cy2, CN, NO 2, ORe1, SRe1, C(O)Rf1, C(O)NRg1Rh1, C(O)ORe1, OC(O)Rf1, OC(O)NRg1Rh1, NRg1C(O)NRg1Rh1, NRg1Rh1, NRg1C(O)Rf1, NR91C(O)ORe1, C(=NRi)NRg1Rh1, NRg1C(=NRi)NRg1Rh1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rf1, S(O)NRg1Rh1, S(O)2Rf1 i S(O)2NRg1Rh1；R5b je H, C1-8alkil, C2-8alkenil, C2-8alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil gde su spomenuti C1-8alkil, C2-8 alkenil, C2-5alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil opciono supstituisani sa 1, 2, 3, 4 ili 5 supstituenata nezavisno izabranih od halo, C1-6 alkila, C2-6 alkenilaC2-6 alkinila, C1-4 haloalkila, C1-4 h
